Devices › Heart-valve, non-allograft tissue
Device brand name · Heart-valve non-allograft tissue
Trifecta Stented Tissue Valve: medical device reports filed with FDA
290 reports name it, 2013–2022. Manufacturer given most often on reports: St Jude Medical Costa Rica Ltda. Product code LWR.
- 290
- device reports naming the brand
- 0% of all MAUDE reports · about 22 a year
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 1.4%
- classified as malfunction
- 4.9% across the product code
- 7.9%
- classified as death, as reported
- 23 reports · not verified by FDA
290 medical device reports received by FDA name the brand "Trifecta Stented Tissue Valve" (heart-valve non-allograft tissue); the manufacturer given most often on reports is St Jude Medical Costa Rica Ltda; received from April 2013 to February 2022. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (90.3%), death (7.9%) and malfunction (1.4%); across all heart-valve, non-allograft tissue reports (product code LWR) death is recorded in 8% and malfunction in 4.9%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are insufficient device problem information (22.8%), material split, cut or torn (14.8%) and obstruction of flow (8.6%). The patient problems coded most often are endocarditis, aortic insufficiency and aortic regurgitation. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 25,638 reports carrying product code LWR. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Insufficient device problem information | 66 | 22.8% | 25.2% |
| Material split, cut or torn | 43 | 14.8% | 3.6% |
| Obstruction of flow | 25 | 8.6% | 2.2% |
| Leak/splashthe device leaked | 20 | 6.9% | 2.1% |
| Backflow | 16 | 5.5% | 1.5% |
| Gradient increase | 13 | 4.5% | 6.1% |
| Biocompatibility | 11 | 3.8% | 0.6% |
| Calcified | 9 | 3.1% | 5.7% |
| Torn material | 9 | 3.1% | 1.3% |
| Device operates differently than expectedthe device behaved unexpectedly | 7 | 2.4% | 0.9% |
| Incomplete coaptation | 7 | 2.4% | 3.1% |
| Degraded | 4 | 1.4% | 3.7% |
| Microbial contamination of device | 4 | 1.4% | 0.4% |
| Detachment of device component | 3 | 1% | 0.1% |
| Infusion or flow problema problem with flow or infusion | 3 | 1% | 0.1% |
| Occlusion within devicethe device blocked | 3 | 1% | 0.8% |
| Perivalvular leak | 3 | 1% | 6% |
| Breakthe device broke | 2 | 0.7% | 0.3% |
| Entrapment of device | 2 | 0.7% | 0% |
| Improper flow or infusion | 2 | 0.7% | 0% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Endocarditis | 39 | 13.4% |
| Aortic insufficiency | 37 | 12.8% |
| Aortic regurgitation | 35 | 12.1% |
| Deaththe patient died; cause not stated by this term | 19 | 6.6% |
| Aortic valve stenosis | 13 | 4.5% |
| Dyspneashortness of breath | 12 | 4.1% |
| Stroke/cva | 12 | 4.1% |
| Cusp tear | 11 | 3.8% |
| Heart failure | 10 | 3.4% |
| Hemorrhage/blood loss/bleeding | 10 | 3.4% |
| Aortic valve insufficiency/ regurgitation | 8 | 2.8% |
| Complete heart block | 7 | 2.4% |
| Corneal pannus | 7 | 2.4% |
| Calcium deposits/calcification | 6 | 2.1% |
| Congestive heart failure | 6 | 2.1% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Trifecta Stented Tissue Valve | Product code LWR | All MAUDE reports |
|---|---|---|---|
| Reports | 290 | 25,638 | 26,136,888 |
| Share of that pool | — | 1.1% | 0% |
| Classified as death, per 1,000 reports | 79 | 80 | 9 |
| Classified as injury | 90.3% | 86.2% | 36.2% |
| Classified as malfunction | 1.4% | 4.9% | 62.3% |
| Filed by the manufacturer | 100% | 95.7% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code LWR
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Freestyle Aortic Root Bioprosthesis | 2,344 | 202 | 6% |
| Edwards INSPIRIS RESILIA Aortic Valve | 2,035 | 599 | 0.8% |
| Sjm Trifecta Valve | 1,525 | 0 | 8.1% |
| Perceval Sutureless Aortic Heart Valve | 1,473 | 18 | 9.1% |
| Mosaic Aortic Bioprosthetic Heart Valve | 3,406 | 405 | 2.8% |
| Carpentier-Edwards Perimount Pericardial Bioprosthesis | 978 | 1 | 10% |
| Carpentier-Edwards Bioprosthesis | 1,055 | 3 | 5% |
| Mosaic Mitral Bioprosthetic Heart Valve | 1,534 | 154 | 6.4% |
| Carpentier-Edwards PERIMOUNT Plus Pericardial Bioprosthesis | 2,878 | 18 | 8.7% |
| Carpentier-Edwards Perimount Magna Aortic Bioprosthesis | 1,324 | 11 | 27.1% |
| Carpentier-Edwards Perimount Rsr Pericardial Bioprosthesis | 3,288 | 13 | 3.3% |
| Trifecta GT Valve | 674 | 66 | 9.5% |
| EDWARDS INTUITY ELITE Valve System | 677 | 62 | 2.2% |
| Avalus Aortic Tissue Valve | 652 | 133 | 11% |
| INSPIRIS RESILIA Aortic Valve | 532 | 87 | 0.4% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Trifecta Stented Tissue Valve reports
How many FDA reports name Trifecta Stented Tissue Valve?
290 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
injury (90.3%), death (7.9%) and malfunction (1.4%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
insufficient device problem information (22.8%), material split, cut or torn (14.8%), obstruction of flow (8.6%), leak/splash (6.9%) and backflow (5.5%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Trifecta Stented Tissue Valve was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.